Article
Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension.
Nutrition (Burbank, Los Angeles County, Calif.) - 1 May 2021
King Susannah J, Tierney Audrey C, Edgeworth Deirdre, Keating Dominic, Williams Elyssa, Kotsimbos Tom, Button Brenda M, Wilson John W
Abstract excerpt
OBJECTIVES: In patients with cystic fibrosis (CF) who carry the G551D mutation, treatment with ivacaftor improves lung function and weight; however, short- and long-term impacts on body composition have not been well studied. METHODS: Twenty adults with CF carrying the G551D mutation (mean ± standard deviation body mass index [BMI] 23.3 ± 4.3 kg/m2) were recruited for a single-center, double-blind,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.